Sanofi's Diabetes Drug Cleared for EU Nod

By Joshua Kirby

Sanofi's Teizeild treatment for diabetics has been given a positive opinion by European Union regulators, paving the way for the treatment to be rolled out across the bloc.

The French pharmaceutical company said Friday that the European Medicines Agency had recommended approval of Teizeild, or teplizumab, for treatment in adults and older pediatric patients with stage-2 type-1 diabetes, or T1D. The treatment aims to delay the onset of stage-3 T1D.

The recommendation follows trial data showing that Teizeild significantly delayed the onset of the next stage of the disease in many patients, Sanofi said.

"We are encouraged by the positive opinion in stage-2 T1D, which represents an important step toward transforming the 100-year-old treatment paradigm for autoimmune T1D," said Olivier Charmeil, Sanofi's executive vice president for general medicines.

Write to Joshua Kirby at [e-mail]; @joshualeokirby

(END) Dow Jones Newswires

11-14-25 0705ET